X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (83) 83
female (79) 79
oncology (69) 69
ovarian cancer (56) 56
index medicus (54) 54
middle aged (48) 48
aged (42) 42
ovarian neoplasms - drug therapy (41) 41
cancer (39) 39
chemotherapy (39) 39
ovarian neoplasms - pathology (39) 39
adult (36) 36
obstetrics & gynecology (34) 34
carcinoma (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
prognosis (28) 28
neoplasm staging (25) 25
aged, 80 and over (24) 24
paclitaxel (22) 22
surgery (22) 22
disease-free survival (21) 21
paclitaxel - administration & dosage (21) 21
ovarian neoplasms - surgery (20) 20
survival (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
carboplatin - administration & dosage (19) 19
ovarian neoplasms - mortality (18) 18
treatment outcome (18) 18
tumors (18) 18
analysis (17) 17
research (17) 17
carboplatin (15) 15
clinical trials (15) 15
hematology, oncology and palliative medicine (15) 15
1st-line treatment (14) 14
cisplatin (14) 14
intergroup trial (14) 14
oncology, experimental (14) 14
ovarian carcinoma (14) 14
survival analysis (14) 14
quality of life (13) 13
care and treatment (12) 12
combined modality therapy (12) 12
cisplatin - administration & dosage (11) 11
ovarian neoplasms - therapy (11) 11
prospective studies (11) 11
young adult (11) 11
gynecologic-oncology-group (10) 10
immunohistochemistry (10) 10
recurrence (10) 10
retrospective studies (10) 10
expression (9) 9
neoplasm recurrence, local - drug therapy (9) 9
ovarian neoplasms - diagnosis (9) 9
ovarian neoplasms - genetics (9) 9
stage-iii (9) 9
women (9) 9
bevacizumab (8) 8
cancer patients (8) 8
germany (8) 8
medicine & public health (8) 8
obstetrics and gynecology (8) 8
randomized controlled trials as topic (8) 8
survival rate (8) 8
deoxycytidine - administration & dosage (7) 7
deoxycytidine - analogs & derivatives (7) 7
epithelial ovarian (7) 7
kaplan-meier estimate (7) 7
management (7) 7
pathology (7) 7
proportional hazards models (7) 7
randomized-trial (7) 7
trial (7) 7
clinical-trials (6) 6
cyclophosphamide (6) 6
diagnosis (6) 6
drug resistance, neoplasm (6) 6
follow-up studies (6) 6
health aspects (6) 6
multivariate analysis (6) 6
paclitaxel - adverse effects (6) 6
patients (6) 6
secondary cytoreductive surgery (6) 6
time factors (6) 6
tumor (6) 6
antineoplastic agents - therapeutic use (5) 5
breast-cancer (5) 5
carcinoma, ovarian epithelial (5) 5
chemotherapy, adjuvant (5) 5
clinical trials, phase iii as topic (5) 5
cytoreductive surgery (5) 5
des cancers (5) 5
drug administration schedule (5) 5
flow cytometry (5) 5
gynecology (5) 5
infusions, intravenous (5) 5
male (5) 5
medical oncology (5) 5
metastasis (5) 5
mutation (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 06/2017, Volume 40, Issue 6, pp. 383 - 383
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 928 - 936
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 3, pp. 236 - 243
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 12, pp. 1554 - 1561
Journal Article
Journal Article
12.